Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00432744 · ClinicalTrials.gov registry record · Phase 3
Phase III Trial of Coenzyme Q10 in Mitochondrial Disease
A Phase 3 study of Mitochondrial Diseases, sponsored by University of Florida.
- Completed
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
- 3
- Study locations
NCT00432744 is a Phase 3 study of Mitochondrial Diseases that has completed, run by University of Florida. The registered enrollment target is 24 participants, below the 273-participant average among 7 other Mitochondrial Diseases trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00432744, a Phase 3 study of Mitochondrial Diseases, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
- 3
- Study locations
Study Summary
To show that oral CoQ10 is a safe and effective treatment for children with inborn errors of mitochondrial energy metabolism due to defects in specific respiratory chain (RC) complexes or mitochondrial DNA (mtDNA) mutations, and that this beneficial action is reflected in improved motor and neurobehavioral function.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CoenzymeQ10
Study Locations (3)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Case Western Reserve University - Cleveland
Ontario
- Hospital for Sick Children - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-01 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00432744
The ClinicalTrials.gov registry entry for NCT00432744 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 273-participant average among 7 other Mitochondrial Diseases trials with a reported enrollment target (91% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mitochondrial Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00432744 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Ontario.
Frequently Asked Questions
What is clinical trial NCT00432744 about?
NCT00432744 is a clinical study titled "Phase III Trial of Coenzyme Q10 in Mitochondrial Disease". To show that oral CoQ10 is a safe and effective treatment for children with inborn errors of mitochondrial energy metabolism due to defects in specific respiratory chain (RC) complexes or mitochondrial DNA (mtDNA) mutations, and that this beneficial action is reflected in improved motor and neurobeh...
What is the current status of trial NCT00432744?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2007-01. Estimated completion is 2013-05.
What conditions does trial NCT00432744 study?
This clinical trial studies the following conditions: Mitochondrial Diseases.
What interventions are being tested in trial NCT00432744?
The interventions under investigation include: Placebo (DRUG), CoenzymeQ10 (DRUG).
Who is sponsoring clinical trial NCT00432744?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00432744 being conducted?
This trial has 3 study locations across Ohio, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mitochondrial Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
RECRUITING · Phase 3
-
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
RECRUITING
-
Validation of Oxygen Nanosensor in Mitochondrial Myopathy
RECRUITING · Phase 1
-
Applying pGz in Mitochondrial Disease
RECRUITING · Phase 1
-
Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders
RECRUITING
-
Heart Rate Variability in Response to Metformin Challenge
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.